INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIK

Core Viewpoint - Anika Therapeutics is under investigation for potential securities fraud following the announcement of disappointing clinical trial results for its product Hyalofast, which led to a significant drop in stock price [1][2]. Group 1: Company Overview - Anika Therapeutics, Inc. is a publicly traded company on NASDAQ under the ticker ANIK [1]. - The company focuses on developing innovative therapies for tissue regeneration and repair [2]. Group 2: Clinical Trial Results - On July 30, 2025, Anika announced topline results from a pivotal clinical trial of Hyalofast, a resorbable hyaluronic acid scaffold for cartilage repair [2]. - The trial showed consistent improvements in treated patients compared to microfracture, but did not meet its pre-specified co-primary endpoints [2]. - Factors affecting the trial results included a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and a reduced evaluable sample size [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Anika's stock price fell by $3.06 per share, or 27.42%, closing at $8.10 per share on July 30, 2025 [2].